comprehensive -WSS

comprehensive

author：Wikipedia 2025-09-02 09:41:57 - browse：9

light shines behind Pfizer CEO Albert Bourla as he attends a ceremony in Greece — Pfizer CEO Albert Bourla was one of a few pharmaceutical executives who donated to a failed Senate campaign in New Jersey. Giannis Papanikos/AP

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays.

Administration infighting over the national stockpile

The health department’s preparedness office overseeing national stockpiles of emergency medical gear is trying to cement its Covid-era power — and meeting with congressional skepticism.

The Administration for Strategic Preparedness and Response has seen demands for protective gear and therapies rapidly expand between the Covid-19 pandemic, the 2022 mpox outbreak, and now the spread of avian flu among cows. But its management of the nation’s medical stockpile — and its efforts to replenish depleting stock — are under fresh scrutiny from lawmakers. In particular, Republicans want answers on the $850 million that Congress clawed back from ASPR’s budget, and on why that cash wasn’t spent if the stockpile needed it so badly, my co-author Sarah Owermohle reports.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： U.K. sequencing study surfaces new findings about tumor DNA

WSS

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

The Karikó problem: Lessons for funding basic research

Study points to new risk in gene therapy death of Terry Horgan

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Stop Congress from blocking public access to science

The biotech scorecard for Q1: 17 stock

hotspot

comprehensive

Administration infighting over the national stockpile

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Heart attack and stroke risk calculators need revising

WHO recommends second malaria vaccine

Dobbs anniversary: the lost opportunity of abortion as health care

GSK Flovent asthma inhalers replaced by authorized generics

Trump demands the U.S. pay no more for drugs than other countries … again

The FDA must approve intranasal treatments for anaphylaxis

The cancer drug shortage isn’t new — and neither are the solutions

The Karikó problem: Lessons for funding basic research

Sports medicine is finally prioritizing gender equality

A single drug, study failures leave Anavex with nothing but cash

entertainment

The FDA must approve intranasal treatments for anaphylaxis

Nobel honors Karikó and Weissman's enduring partnership

CRISPR base editing slashes cholesterol levels in monkeys

UCB departs biotech trade group BIO

Health insurers' Q3 question: how much care are people getting?

Setback for rare diseases as Taysha Gene Therapies pulls back

focus

hotspot

hotspot

focus